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ABSTRACT 
Antimicrobial resistance is a big problem in modern medicine. One of the key components in 
the combat is the characterization of novel drug targets and the development of new classes of 
compounds targeting them. In the case of the gastric pathogen Helicobacter pylori, increasing 
resistance necessitates more elaborate and costly treatment-regimes, which cause more side 
effects than the standard therapy. As for Bacillus anthracis, the causative agent of anthrax, 
naturally occurring or engineered resistance threatens to compromise the treatment of infections 
caused by this severe pathogen. 
 
The aim of this thesis was to characterize bacterial thioredoxin systems as potential drug 
targets in bacteria devoid of glutathione. Furthermore, to develop inhibitors that targets these 
systems. Special emphasis was given to H. pylori as a representative for slow growing, chronic, 
pathogens and B. anthracis for rapidly growing pathogens giving rise to fulminant disease. 
 
Paper nr I: We provided crystal structures of H. pylori thioredoxin reductase in both the 
oxidized and reduced forms at 1.7 and 1.45Å resolution, respectively. This information could 
potentially be used for rational design and optimization of inhibitors. 
 
Paper nr II: We characterized the thioredoxin system of B. anthracis and concluded that, 
despite an apparent redundancy, B. anthracis has only one thioredoxin reductase, two 
thioredoxins and one NrdH-redoxin. Furthermore, thioredoxin 1 was the predominant disulfide 
reductase and the physiologically relevant electron donor for ribonucleotide reductase. This 
suggests that the thioredoxin system of B. anthracis could be an attractive drug target. 
 
Paper III: We described inhibition of bacterial thioredoxin reductases as a novel antibiotic 
principle using ebselen. Using pure proteins, we could show that ebselen is a competitive 
inhibitor of E. coli thioredoxin reductase, acting by binding to the C-terminal active site 
cysteine. We used various E. coli strains with gene-deletions in the redox systems to show that 
the absence of glutathione confers sensitivity to ebselen. We also showed that H. pylori and M. 
tuberculosis, both of which naturally lack glutathione, are sensitive to the drug. 
 
Manuscript IV: We studied ebselen and derivatives thereof as inhibitors of B. anthracis 
thioredoxin reductase and tested their antibacterial activity against B. subtilis. We could show 
that selected compounds are potent inhibitors of B. anthracis thioredoxin reductase with IC50 
values down to 70 nM. Minimal Inhibitory Concentrations (MICs) were down to 0.4 µM 
(0.12µg/ml) for B. subtilis and compounds had a bacteriocidal mode of action. Based on this, 
we constructed a structure-activity-relationship and concluded that ebselen and derivatives 
thereof could potentially be used for the treatment of anthrax. 
 
In conclusion, the present thesis deals with the characterization of bacterial thioredoxin 
systems as potential drug targets - on a biochemical, bacteriological and structural level. The 
results obtained suggest that bacterial thioredoxin systems are attractive drug targets in bacteria 
devoid of glutathione and that ebselen might be a viable starting point for drug development. 
Inhibitors could potentially be used to treat a wide variety of infections including anthrax, 
gastric ulcers and tuberculosis. 
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1 INTRODUCTION 
 
1.1 THE PROBLEM OF ANTIMICROBIAL RESISTANCE 
One of the big problems in modern medicine is the increasing antimicrobial 
resistance. Antimicrobial resistance results in increased morbidity, mortality and 
cost. Additionally, it threatens to compromise our ability to cope with infectious 
complications normally associated with surgical procedures, cancer treatments, 
dialysis and transplantations (1). 
 
In an American study, infections with methicillin resistant Staphylococcus aureus 
(MRSA) were associated with almost three times higher mortality compared to 
infections with methicillin sensitive  S. aureus (MSSA) (2). Furthermore, a recent 
report suggests that a selected list of resistant bacterial pathogens are responsible for 
a minimum of 25 000 deaths and increased costs of € 1.5 billion annually in the EU 
(3).  
 
In “the golden era of antibiotics” resistance was not considered a big problem given 
that new classes of antibiotics were continuously being introduced, keeping us 
ahead of resistance. The situation has since changed – few new drugs are being 
approved, and most of them are small variations of a well known scaffold, targeting 
a limited set of functions in the bacteria (3–5). This is illustrated by the β-lactams 
(including the penicillins), a class of antibiotics which has been extensively used 
and varied over the years (6). 
 
The reasons for the lack of new antibiotics are many but can broadly be divided into 
financial, scientific and regulatory (7). One important aspect is the limited potential 
financial gain from developing a new antibiotic. Antibiotics for many infections are 
typically used on a timescale of days-weeks, limiting their market potential. This is 
in contrast to drugs such as antihypertensives and antidiabetics which are typically 
used on a timescale of years (8). Scientific reasons include the problem of 
identifying good antibacterial targets which could give a suitable spectrum of 
activity. Furthermore, the low hit rate observed in screening campaigns against 
bacterial targets is problematic. This is illustrated by the experience from 
GlaxoSmithKline (GSK), which screened up to 530 000 compounds against 70 
different targets over a period of seven years. This returned hits for 14 of the targets, 
with a total of five leads generated. All of these were subsequently dropped from 
further development (9). It has been speculated that a large part of the failures in 
screening for antibacterial compounds can be explained by the inadequate chemical 
libraries available. Most corporate and publicly available libraries are heavily biased 
towards types of compounds active against human drug targets. Furthermore, 
successful antibiotics in clinical use are characterized by significant differences in 
their properties compared to non-antibacterial drugs, including higher polarity, 
smaller size and larger proportion of covalent binders (10). 
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1.1.1 How can we combat antimicrobial resistance? 
 
1.1.1.1 Pathogen identification, susceptibility testing and surveillance 
A key component is pathogen identification and susceptibility testing of clinical 
isolates. This enables targeted therapy, and can help in guiding empirical treatment 
(treatment prior to definite identification of the pathogen and susceptibility testing) 
when combined with surveillance. The combination is also important for limiting 
the spread of resistant organisms and can help in directing the development of new 
antibacterials. 
 
1.1.1.2 Prudent use of a limited resource 
Antibiotics are definitely a limited resource given that the number of suitable drug 
targets in bacteria is relatively low. Furthermore, antibacterial resistance shows a 
clear correlation to the level of usage, both in humans (11–13) and animals (14). In 
many countries, antibiotics are available over the counter without prescriptions and 
are frequently being prescribed on inadequate indications (e.g. for viral infections).  
 
Another important factor to consider is the antimicrobial spectrum of the antibiotics 
– ideally an antibiotic should only target the bacteria causing the infection at hand. 
This reduces the risk of resistance development as well as potential for side effects. 
However, since a large proportion of infections are treated empirically, agents 
targeting only a single bacterium are not always ideal. Typically, rapidly 
progressing, life threatening infections such as meningitis and severe sepsis require 
a broader spectrum of activity. On the other hand, slowly progressing and non-fatal 
infections can be treated with agents with a narrower spectrum, given that the 
causative agent is sensitive. 
 
The use of antibiotics as growth promoters in animal feed is prohibited in the EU, 
but is commonly used elsewhere, including the US, despite minimal production 
gain (15). Even in countries where such a misuse is prohibited, the use of veterinary 
antibacterials for treatment and prophylaxis differs significantly. A European study 
showed that the consumption in ten different countries differed by a factor ten (mg 
antibiotic consumed / kg produced meat) between low consumption countries 
(Sweden, Norway and Finland) and high consumption countries (the Netherlands 
and France) (16). The potential for reduction of use should be obvious. 
 
Release of antimicrobials as a result of manufacturing is another problem which has 
been investigated recently. Effluent from a sewage treatment plant in India, serving 
90 different bulk drug manufacturers, was analyzed for a number of 
pharmaceuticals and high levels of many antibiotics were found. The levels of 
ciprofloxacin in the effluents were 28-31mg/L (17). These concentrations are 30 
times higher than the susceptibility breakpoint for E. coli (R > 1mg/L) and roughly 
ten times higher than the maximal concentration attained in patient serum (Cmax < 3-
4 mg/L) during therapy (18). Given that these effluents were released directly into 
nearby rivers (17), the risk for resistance development should be substantial. 
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In conclusion, a strict antibiotic policy should be implemented where antibiotics are 
only available by prescription, on adequate indications and with a spectrum of 
activity suitable for the indication. This has been advocated for the last 15 years by 
STRAMA (Swedish Strategic Programme for the Rational Use of Antimicrobial 
Agents and Surveillance of Resistance), which has shown that long term changes in 
antibiotic usage can be achieved, at least on a national level (19). Furthermore, 
veterinary use should be drastically reduced, given that animals are generally 
treated with the same classes of antibacterials as humans and that resistant bacteria 
can be transmitted between species (15). 
 
1.1.1.3 Containment and prevention of dissemination 
To avoid spread of resistant organisms within hospitals and to the society, 
adherence to basic hygiene routines (including protective clothing, alcohol based 
hand wash and adequate cleaning procedures) is important. The same goes for 
identification and  isolation of infected or colonized patients (20). There is a strong 
correlation between a low MRSA prevalence and strict adherence to such 
procedures (21). Furthermore, there is an association between implementation of 
strict procedures and a decrease in the prevalence of MRSA (22). 
 
Given that international travels are common nowadays, antimicrobial resistance is 
also spread between countries. In a study on healthy volunteers, with negative pre-
travel samples, traveling from a low-prevalence setting (Sweden) to destinations 
outside of northern Europe, 24 % tested positive for colonization with extended 
spectrum β-lactamase (ESBL) producing bacteria  upon return. Notably, 88% of 
travelers returning from India were ESBL positive (23). This is especially 
problematic given the recent isolation of Gram-negative bacteria expressing the 
NewDelhi metallo-β-lactamase 1 (blaNDM-1). These bacteria are generally resistant 
to most available antibiotics including penicillins, cephalosporins, carbapenems, 
flouroquinolones, tetracyclines and aminoglycosides (24, 25). 
 
1.1.1.4 Development of new antibacterials 
The last part involves the development of new antibacterials, and at the heart of 
antibiotic development is the characterization of potential antibacterial drug targets. 
 
Although antibiotic development is a far from trivial task (7, 9, 10), it needs to be 
continued nevertheless. It has been suggested that new approaches, in the scientific, 
regulatory and commercial parts of the development, need to be adopted (26–28). 
 
One way of rapidly accessing “new” antibiotics is to rediscover old drugs and drug 
candidates which, for various reasons, are not widely available or have not been 
registered. These reasons might include inadequate spectrum of activity, frequent 
side-effects, lower efficiency or unfavorable pharmacokinetics, all of which might 
be acceptable in a situation of increased resistance. In a recent European study, the 
accessibility of many older antibiotics such as fosfomycin and colistin, was found to 
be highly variable and with a large potential for improvement (29). 
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1.2 WHAT IS A GOOD DRUG TARGET? 
It has been suggested that a good drug target is a target for which a drug with 
desirable properties exists. However, this is somewhat of an oversimplification 
which affords little help in the evaluation of new potential drug targets. For the sake 
of simplicity, only the properties of potential antibiotic drug targets will be 
considered here. 
 
1.2.1.1 Essentiality 
A key property is that the targeted function is essential for the bacterium of interest. 
Herein, essentiality is defined as the inability for the bacterium to live or proliferate 
in the absence of said function. Often, drug targets for antibiotics are enzymes that 
take part in biochemical pathways such as the synthesis of DNA, proteins or the cell 
wall. If multiple parallel pathways exist, combined targeting of the different 
isoenzymes is needed. Thus, a target should be essential in its own right or be very 
similar to the ones constituting the redundancy, allowing for parallel targeting (30). 
 
In the literature, there seems to be a great deal of confusion and conflicting views 
about how essentiality of a gene should be defined. In the following scenarios I will 
consider a gene to be essential: 
 
 If the gene can be disrupted or removed from the chromosome only with the 
presence of an extra copy of the gene. This can be supplied either on a 
plasmid or on another location on the chromosome. The extra copy can be 
placed under an inducible promoter, enabling verification that the obtained 
mutants are non-viable or unable to grow without added inducer. 
 
 If the gene of interest is placed under an inducible promoter and the bacteria 
are only able to grow when inducer is added. Care should be taken to avoid 
potential polar effects. 
 
 If the gene of interest can be disrupted or removed only in the presence of 
an additive supplementing for the deficiency introduced. Care should be 
taken to avoid potential polar effects on genes belonging to the same 
operon. Therefore, scarless methods or other methods allowing read-through 
into adjacent genes are preferred. 
 
 
1.2.1.2 Absence, difference or non-essentiality in the host 
If a function is not present in the host, this might be a good starting point for 
consideration as a drug target. An example of a function which is essential in 
bacteria but not present in human cells is the synthesis of the cell wall. This is 
probably a part of the reason why compounds interfering with the synthesis of cell 
wall represent the most common mechanism of action for antibiotics in clinical use 
as well as compounds in development (6). This is illustrated by the β-lactams which 
interferes with cross-linking of the cell wall. 
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Another possibility is that the function of the target is needed in host cells, albeit 
with a large difference between the host function and the bacterial counterpart, 
permitting selective targeting. This is illustrated by trimethoprim, which binds to 
bacterial dehydrofolate reductase with a 1000- fold higher affinity than the human 
counterpart. 
 
Even if identical functions exist in bacteria and humans and the function as such is 
essential for both, this function could potentially be useful as an antibacterial target 
given that the host have additional systems acting as backup. This will be discussed 
in more detail later in relation to the thioredoxin and glutaredoxin systems. 
 
 
1.2.1.3 Assayability  
Let us assume that an essential gene, without any close homologue, in a 
hypothetical bacterium of considerable medical importance has been identified.  
 
In order to develop a new class of antibiotics targeting the function of this gene, 
some kind of assay to detect interference is needed. Since antibacterial targets are 
often enzymes, compounds interfering with the catalytic conversion of a substrate to 
product (enzyme inhibitors) are typically sought after. 
 
Initially, small or large collections of compounds are usually screened for the 
desired property. Ideally, this should be done in an assay which is cheap and easy to 
parallelize. The hits found in the primary screen usually need further optimization 
to generate one or more leads, which can progress into further development. 
Alternatively, compounds can be screened directly on bacteria for growth inhibition 
or some other property that can easily be assessed after which the target can be 
identified. 
 
 
1.2.1.4 Auxiliary information  
Generally, the more you know about the target of interest the better. Auxiliary 
information might for instance include structural information, which can help in 
rational optimization of inhibitors. Sometimes, a detailed protein structure can even 
be used for in silico (in the computer) screening of potential inhibitors, bypassing 
the need for large scale screening of compounds in the laboratory (31). Nonetheless, 
suggested inhibitors also need to be verified experimentally. 
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1.3 HELICOBACTER PYLORI 
Helicobacter pylori is a Gram-negative, slow-growing, microaerophilic rod (32) 
which was isolated in 1983 from patients with chronic gastritis and duodenal and 
gastric ulcers by Barry Marshall and Robin Warren (33) who were awarded the 
2005 Nobel Prize in Physiology or Medicine for their discoveries. Eventually it was 
accepted that peptic ulcer disease is essentially an infectious disease curable by 
antibiotics. Apart from its role in chronic gastritis and gastroduodenal ulcer disease, 
the bacterium has been recognized as a definite carcinogen due to the strong 
correlation to gastric carcinoma and mucosa-associated lymphoid tissue (MALT) 
lymphoma (34, 35). 
 
Estimations suggest that half of the global population is infected, with a higher 
prevalence in developing countries than in industrialized ones (32, 36). In the 
Kalixanda Study, where 1001 randomly selected adults from two communities in 
northern Sweden were subjected to gastroscopy (37), 33.6% were culture positive 
for H. pylori (38) and 4.1% had ulcers with an equal distribution between gastric 
and duodenal localization (39).   
 
How does a bacterium manage to colonize the highly inhospitable environment in 
the stomach? Given that the environment in the stomach is highly acidic (pH 
down to 1-2), an important virulence factor is urease, which converts urea to 
ammonia and carbon dioxide. The ammonia acts as a buffer, allowing the 
bacterium to survive short term exposure of low pH. Other virulence factors 
important for colonization is motility, which permits H. pylori to enter the mucous 
layer, adhesins permitting adhesion to epithelial cells and various toxins giving 
the bacterium access to nutrients (32, 34).  
 
Colonization of the host by H. pylori usually results in a strong inflammatory 
response with a massive production of reactive oxygen species (40). It might seem 
somewhat surprising that the bacterium is able to withstand this oxidative 
onslaught and establish persistent infections, given its strict microaerophilic in 
vitro growth requirements. Some of the systems responsible for protection against 
oxidative stress are thioredoxin dependent (41). 
 
The standard triple therapy consists of a proton pump inhibitor (PPI) and two out 
of three of the following antibiotics: clarithromycin, amoxicillin and 
metronidazole. On a Swedish note, antimicrobial resistance is rather uncommon 
as illustrated by the Kalixanda Study (38) and treatment results are still good. 
Internationally, the picture is very different. Increasing resistance has necessitated 
the development of more elaborate and costly therapies, resulting in increased side 
effects and reduced patient compliance (42–44). Perhaps even more problematic, 
is that these therapies tend to include antibiotics such as levofloxacin, 
moxifloxacin and rifabutin, which are normally reserved for other types of 
infections. The need for development of novel antimicrobials targeting this gastric 
pathogen should be obvious. 
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1.4 BACILLUS ANTHRACIS 
Bacillus anthracis, the causative agent of anthrax, is a Gram-positive, spore-
forming rod. The bacterium derives its name from the Greek word for coal which 
refers to the black, coal-like escars sometimes formed during the cutaneous form of 
infection (45). B. anthracis belongs to the Bacillus cereus group and the same genus 
as the nonpathogenic bacterium B. subtilis which has been used extensively as a 
model organism (46).  
 
B. anthracis has two major virulence plasmids; pOX1 and pOX2. pOX1 encodes 
the tripartite toxin whereas pOX2 encodes genes responsible for synthesis of the 
antiphagocytic poly-D-ɣ-glutamic acid capsule. The tripartite toxin is composed of 
protective antigen (PA) in complex with either lethal factor (LF) or edema factor 
(EF). PA mediates cellular uptake, whereas LF and EF mediates toxicity. Loss of 
either plasmid results in dramatic attenuation of virulence (47). 
 
Anthrax exists in three major forms; cutaneous, inhalational and gastrointestinal. In 
the cutaneous form, spores are introduced through the skin whereas in the 
inhalational form, they are inhaled. In the gastrointestinal form, spores or vegetative 
bacteria are ingested. Spores phagocytized by macrophages germinate 
intracellularly after which lysis occurs and bacteria escape to multiply 
extracellularly (48).  
 
The cutaneous form represents about 95% of reported cases and it has been 
estimated that there are about 2000 global cases annually. The mortality rate  has 
been estimated to be up to 20% for untreated infections and less than 1% with early, 
appropriate treatment (49). Mortality in inhalational anthrax has historically been 
close to 100%, but this can be lowered by early treatment with adequate antibiotics 
and supportive care. Out of the 11 cases found during the 2001 anthrax letter 
attacks, 45% died (50).  
 
In 2000, a Norwegian heroin user succumbed to a fourth form of anthrax which was 
named injectional anthrax due to the route of administration (sc. injection) (51). In 
late 2009, Scotland experienced an epidemic of injectional anthrax with a total of 31 
cases, out of which 11 died (52). Additional cases were identified in other parts of 
the UK and Germany (49). Although it was originally assumed that the heroin had 
been contaminated in Afghanistan, a recent molecular epidemiological investigation 
suggest that contamination along the trade route was more likely, given the high 
degree of similarity to Turkish isolates (53). 
 
During the course of a infection, vegetative B. anthracis cells divide rapidly in the 
host and can reach densities of up to 10
7
 - 10
8
 bacteria per milliliter blood (48). The 
rapid growth necessitates efficient systems for synthesis of deoxyribonucleotides 
required for replication and repair of DNA. Additionally, the need for systems 
protecting the bacterium against oxidative stress imposed by the host immune 
system should be obvious. 
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Naturally occurring strains of B. anthracis are generally sensitive to a number of 
commonly used antibiotics including flouroqinolones, tetracyclines, penicillins and 
aminoglycosides (54). Current guidelines usually recommend the combination of a 
flouroquinolone or doxycycline with 1-2 additional antibiotics as empirical 
treatment for symptomatic patients. In a situation of suspected mass-exposure, such 
as after intentional release in a terrorist attack, post exposure prophylaxis with either 
ciprofloxacin or doxycycline is recommended  (55, 56).   
 
Disturbingly, resistance to most relevant antibiotics can easily be selected for in 
vitro (57), which could prove to be disastrous in a scenario intentional release. B. 
anthracis is also naturally resistant to most cephalosporins (45), which is a 
cornerstone in the empirical treatment of serious infections such as pneumonia, 
sepsis and meningitis. 
  
   9 
 
1.5 RIBONUCLEOTIDE REDUCTASE 
Deoxyribonucleic acid (DNA) is the macromolecule responsible for maintaining the 
genetic information in all living cells. To be able to replicate and repair DNA, a 
balanced supply of the monomer building blocks, deoxyribonucleoside triphosfates 
(dNTPs), is required.  
 
During the 1950s, Peter Reichard and colleagues made the observation that 
ribonucleosides were incorporated into both RNA and DNA (58), whereas 
deoxyribonucleosides could only be incorporated into DNA, leading to the 
conclusion that there was an enzymatic activity responsible for the conversion of 
ribonucleosides to deoxyribonucleosides (59). This eventually led to the discovery 
of ribonucleotide reductase (RNR) in extracts of E. coli (60, 61) which was 
subsequently found to contain a stable tyrosyl radical (62) localized to tyrosine 122 
(63). Although this was the first protein radical to be discovered, radicals have been 
found in many different proteins since (64). 
 
RNR catalyzes the conversion of ribonucleotides to deoxyribonucleotides as 
outlined schematically in Figure 1, and respresents the only mechanism for de novo 
synthesis of deoxyribonucleotides making it essential in most organisms (65). 
 
 
 
 
 
 
Figure 1. Conversion of ribonucelotides to deoxyribonucleotides. Ribonucelotide 
reductase (RNR) converts ribonuleotides to deoxyribonucleotides. The most common 
substrates are diphosphates (PP) which are then phosphorylated to triphosphates, whereas a 
few RNRs use triphosphates directly (PPP). The hydroxyl group (OH) which is exchanged 
for a hydrogen atom (H) is highlighted in bold. The base is adenine (A), thymidine (T), 
cytosine (C) or guanine (G). 
 
 
The seemingly simple reaction requires a quite complicated catalytic mechanism 
involving the generation of a stable radical, a long range transfer of the radical and 
the supply of two electrons from an external electron donor (65).  The enzymatic 
activity is subject to a complex allosteric regulation to ensure a balanced supply of 
dNTPs (66, 67).  
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1.5.1 Different classes of RNR 
There are three major classes of RNR, which differ in their overall structure, metal-
cofactor requirement, tolerance or requirement for oxygen and use of external 
electron donor (65). RNRdb (www.rnrdb.molbio.su.se) is a manually curated 
database, collecting information about ribonucleotide reductases in various 
organisms (68). This is a veritable treasure trove for RNR scientists. Below, some 
aspects of the different RNRs will be discussed with a focus on their role for 
proliferation and virulence in different bacteria. 
 
1.5.1.1 Class I – aerobic 
Class I enzymes contain two major subgroups (Ia and Ib) differing in their genomic 
organization, metal cofactor requirement and allosteric regulation of activity (65, 
66). The recently proposed subgroup Ic (69), will not be discussed further in this 
thesis.  
 
Common for the class is that the protein is made up of two different nonidentical 
subunits (NrdA (α) and NrdB(β) for Ia and NrdE (α) and NrdF(β) for Ib) typically 
found in an α2β2 configuration.  The radical is generated on a tyrosine residue in the 
β subunit which is then transferred to a cysteine in the active site of the α subunit, 
giving rise to the catalytic cysteinyl radical. During the course of a catalytic cycle, a 
disulfide is generated in the active site. This disulfide is reduced by the C-terminal 
cysteines located on flexible tail, which swings into the active site. The C-terminal 
disulfide is in turn reduced by external electron donors which can be glutaredoxin, 
thioredoxin or NrdH redoxin depending on the type of RNR and species. Since the 
formation of the radical is oxygen dependent, type I RNRs are only active in the 
presence of oxygen (aerobic conditions) (65).  
 
Type Ia RNRs, as exemplified by the E. coli enzyme, contain an iron cofactor in the 
β-subunit which is essential for radical generation. This particular type of RNR is 
usually the only RNR present in higher eukaryotes such as humans, but is also 
frequently found in bacteria capable of growing under anaerobic conditions together 
with class II and/ or class III enzymes (68).   
 
The first type Ib RNR was identified in Salmonella typhimurium as a gene able to 
complement a temperature sensitive mutant of the type Ia RNR in E. coli (70). The 
protein was recombinantly expressed in E. coli and was characterized as having an 
iron  cofactor and the ability to use glutaredoxin but not thioredoxin as electron 
donor (71).  However, a growing body of evidence suggests that type Ib RNRs 
instead use a manganese cofactor (72–76), where NrdI, a small flavodoxin-like 
protein, is needed for radical generation (77–79). Some of this development has 
recently been summarized (80). Interestingly, type Ib enzymes appears to be 
completely absent from the genomes of eukaryotes (including humans), but are 
common in bacteria, most of which do not encode other aerobic RNRs (68). This 
suggests that type Ib RNRs could be viable drug targets given that inhibitors 
targeting type Ib but not Ia RNRs can be found. 
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1.5.1.2 Class II – aeroboindifferent 
Class II RNRs neither requires nor is inhibited by oxygen and can thus be classified 
as indifferent to oxygen, or aeroboindifferent. They contain a single α-subunit 
(NrdJ) and generate the cysteinyl radical with the help of adenosylcobolamin 
instead of a separate β-subunit. Thioredoxins or glutaredoxins are used as external 
electron donors (66). Class II enzymes predominantly exist in bacteria, some of 
which also contain class I and/or class III enzymes (68). 
 
 
1.5.1.3 Class III – anaerobic 
Class III RNRs are only active under anaerobic (oxygen free) conditions. Two 
different subunits are required for activity; the large catalytic subunit (NrdD) and 
the small radical generating unit (NrdG). NrdG contains a redox active iron-sulfur 
cluster, which together with S-adenosyl methionine (SAM) and reduced flavodoxin 
generates the radical. The radical is sensitive to oxygen, thus explaining the proteins 
general sensitivity to oxygen (66). The external electron donor for class III enzymes 
is formate (81). Class III RNRs are most often found in bacteria and are absent from 
most eukaryotes including humans. In bacteria, class III enzymes are found both in 
strict and  facultative anaerobes. In the latter, they are combined with class I and/ or 
class II enzymes (68). 
 
 
1.5.2 A closer look at RNR in selected bacteria 
 
Some bacteria deserve a closer examination of their RNR with a focus on 
essentiality and role in virulence. E. coli does so, on the basis of its well 
characterized history and role as reference organism, whereas the other bacteria are 
in more direct focus of this thesis. 
 
 
1.5.2.1 Escherichia coli 
Most strains of E. coli with available sequence information contains one Ia, one Ib 
and one class III RNR (68). The presence of both aerobically and anaerobically 
active RNRs is expected given that the bacterium is a facultative anaerobe. 
However, the presence of both a class Ia and a Ib RNR is a bit more surprising. 
 
Despite the presence of two aerobic RNRs in E. coli, the type Ia is essential under 
aerobic conditions unless the type Ib is overexpressed (82–84). In a recent study, E. 
coli could survive solely on its type Ib RNR when subjected to iron starvation, 
H2O2-stress or supplementation of the growth medium with high levels of 
manganese (75). This might indicate a role for the type Ib RNR under iron-deprived 
conditions such as during an infection. To limit the access to iron for the microbe is 
an important defense strategy for the host. 
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In a series of experiments, it was shown that both of the subunits of class III RNR in 
E. coli are essential for growth under strict aerobic conditions. However, even trace 
amounts of oxygen was enough to promote growth by the class I enzymes (85). 
This was later verified (84). 
 
 
1.5.2.2 Helicobacter pylori and Campylobacter jejuni 
H. pylori contains only a single type Ia RNR (86), which might explain its inability 
to grow under anaerobic conditions. So far, no experimental data has been 
published regarding RNR from this gastric pathogen.  
 
The closely related microaerophile Campylobacter jejuni, which causes colitis and 
diarrhea, also encodes a single Ia RNR (87) and is unable to grow under strict 
anaerobic conditions. In a recent study, the authors showed that C. jejuni is able to 
respire without oxygen as the terminal electron acceptor. On the other hand, DNA 
synthesis was inhibited. Anaerobic conditions resulted in filamentation, a 
morphology also seen when bacterial cultures were treated with hydroxyurea – a 
well known inhibitor of ribonucleotide reductases (88). 
 
Whether or not RNR in these bacteria could be viable drug targets remains to be 
established. This is far from obvious given that humans also rely on type Ia RNRs 
for synthesis of deoxyribonucleotides.  However, one could imagine inhibitors 
selective for the bacterial enzymes or compounds which are not absorbed from the 
gastrointestinal tract, thus giving low systemic exposure. 
 
 
1.5.2.3 Bacillus anthracis, cereus and subtilis 
B. anthracis, B. cereus and B. subtilis all have type Ib RNRs but not type Ia RNRs 
(68). On a general note B. subtilis seems to be missing anaerobic RNRs whereas 
most B. cereus and some of B. anthracis strains appear to have genes encoding for 
type III RNRs. 
 
Both subunits of the type Ib RNR are essential for growth of B. subtilis under 
aerobic conditions on rich media (89). To the best of my knowledge, essentiality of 
the corresponding genes in B. cereus and B. anthracis has not been investigated. 
However, it seems likely that they are essential under aerobic conditions. 
 
Whether or not B. subtilis is able to grow under strict anaerobic conditions without 
exogenously added deoxyribonucleotides, is still under debate (90, 91). 
 
The iron form of the type Ib RNR from B. anthracis has been studied as a potential 
drug target. Compounds showing a selective inhibition over type Ia RNRs in vitro 
were identified (92, 93). Certain compounds showed some activity against B. 
anthracis and a moderate selectivity relative to E. coli (92).  
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1.5.2.4 Staphylococcus aureus 
S. aureus is a Gram-positive cocci, capable of growing both aerobically and 
anaerobically. It is an important human pathogen causing a wide variety of clinical 
conditions including endocarditis, septicemia as well as skin and soft tissue 
infections (94). 
 
S. aureus encodes one class Ib and one class III RNR. The class III RNR, which is 
essential for anaerobic growth of S. aureus (95), was  shown to be highly important 
for virulence in a mouse model of septic arthritis, and for the ability of the 
bacterium to persist in the kidney parenchyma after an intravenous challenge (96). 
 
Although essentiality of the type Ib RNR for aerobic growth of S. aureus has not 
been formally shown, it is likely, given the results from a transposon based study, 
which suggest that both NrdE and NrdF are essential (97). In another study, the type 
Ib enzyme was characterized in its pure form and was found to be active (98). The 
low activity found could likely be explained by the use of an iron-loaded form of 
NrdF. 
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1.6 THE THIOREDOXIN AND GLUTAREDOXIN SYSTEMS 
Many organisms, including E. coli and man, have two major protein disulfide 
reductase systems – the thioredoxin and the glutaredoxin system (Figure 2). The 
thioredoxin system is composed of NADPH, thioredoxin reductase (TR) and 
thioredoxin (Trx) shuttling electrons to the terminal substrates (99). When present, 
NrdH can also be considered a part of the thioredoxin system as discussed later in 
the introduction. The glutaredoxin system on the other hand consists of NADPH, 
glutathione reductase (GR), glutathione (GSH) and glutaredoxin (Grx) (100). 
 
 
 
Figure 2. The thioredoxin and glutaredoxin system.  
 
 
1.6.1 Thioredoxin 
Thioredoxin was originally discovered in E. coli as a hydrogen donor for 
ribonucleotide reductase (RNR) (101). Four years later, the amino acid sequence 
was elucidated (102) and in 1975, the first high-resolution structure was presented 
(103). 
 
Thioredoxins are small (approx. 12 kDa), heat stable proteins with a well 
characterized fold. The thioredoxin fold is composed of a central β-sheet 
surrounded by α-helices. Although the minimal Trx fold requires four β-strands and 
three α-helices (104), thioredoxin as exemplified by E. coli Trx1 contain a five-
membered β-sheet surrounded by four α-helices (103). The thioredoxin fold is 
present in a wide variety of proteins with different functions including 
glutaredoxins, NrdH redoxins, protein disulfide isomerases and glutathione S-
transferases (104). Thioredoxins typically have WCGPC active sites, but exceptions 
do exist as exemplified by Trx2 from H. pylori which has a WCPDC active site 
(105) and by Trx2 from B. anthracis as discussed in paper II (106). 
 
Flow of electrons
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In addition to its role as an electron donor for RNR, thioredoxin also acts as a 
general protein disulfide reductase with an important role in upholding of the 
reducing intrecellular milieu and protection against oxidative stress (107–109). 
Specific disulfide targets include methionine sulfoxide reductase (MSR), 3’-
phosphoadenylylsulfate (PAPS) reductase (110), and thioredoxin dependent 
peroxiredoxins (111, 112). 
 
PAPS reductase catalyses the conversion of 3’-phosphoadenylylsulfate (PAPS) to 
sulfite and is required for sulfur assimilation from sulfate. PAPS reductase is 
generally essential in bacteria unless a reduced sulfur source such as methionine, 
cysteine or glutathione is present. MSR on the other hand reduces methionine 
sulfoxides in proteins and is important for protection against oxidative stress (113). 
The same goes for the peroxiredoxins which scavenge organic and inorganic 
peroxides (114). 
 
Thioredoxin also has a number of functions which does not involve the transfer of 
electrons to a substrate, but rather where it acts as a structural component. The most 
well-known of these is perhaps E. coli thioredoxin and its role as a subunit of the 
phage T7 DNA polymerase, for which it required for activity (115–117). 
 
 
1.6.2 NrdH 
NrdH was identified as an electron donor for the type 1b RNR from Lactococcus 
lactis with a CMQC active site (118). Further characterization of the E. coli 
counterpart, with a CVQC active site, revealed a thioredoxin activity profile despite 
the sequence similarity to glutaredoxins. It was speculated that this might result 
from the inability to bind GSH (119) which was later confirmed by the crystal 
structure that showed the absence of a GSH binding site in NrdH. Furthermore, the 
structure suggested a putative TR binding patch, explaining the ability for TR 
dependent reduction (120). 
 
 
1.6.3 Thioredoxin reductase 
Thioredoxin reductases are widely distributed, FAD containing enzymes which  
catalyze the NADPH-dependent reduction of thioredoxins and NrdH-redoxins 
(121). Thioredoxin reductase was dicovered in, and partially purified from, E. coli 
in parallel with the work on thioredoxin (122). It was further purified and 
characterized a few years later (123). 
 
The most well studied TR is E. coli enzyme, for which crystal structures have been 
determined of several different forms. This includes the C138S in oxidized, FO 
form (124), wild type in oxidized FO form (125) and fully reduced FO form (126). 
Finally, the structure of a complex of E. coli TR C135S trapped in a complex with 
an active site mutant (C35S) of E. coli Trx1 was published in 2000 (127). 
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Whereas thioredoxins from most species show a high degree of structural and 
functional similarity, this is not the case for their respective reductases. Two major 
groups have evolved. The low molecular weight group is exemplified by the 
bacterial enzymes and the high molecular weight group is exemplified by the 
mammalian enzymes (121).  
 
 
1.6.3.1 Bacterial thioredoxin reductases 
The bacterial enzymes have a subunit weight of 35 kDa and utilize a CAT/VC 
active-site. The active site is positioned in a crevice in the central parts of the 
molecule, and the enzyme needs to undergo a 67 degree domain rotation during 
their catalytic cycle alternating between the FO and the FR forms (127). The flow 
of electrons is from NADPH via FAD to the active-site disulfide (121). The 
substrate specificity of the bacterial thioredoxin reductase group is generally quite 
narrow and is largely confined to its respective thioredoxins, and when present, 
NrdH (119).  
 
 
1.6.3.2 Mammalian thioredoxin reductases 
The mammalian enzymes on the other hand, have a subunit weight of about 55 kDa 
and show a high degree of structural similarity to glutathione reductases (128). 
They utilize a GCUG active-site, where U is the unusual and highly reactive amino 
acid selenocysteine, positioned at a flexible C-terminal extension (129). The flow of 
electrons is from NADPH via the FAD and the N-terminal redox-center to the 
selenosulfide which then reduces the substrate (130). The mammalian enzymes 
have a much broader substrate specificity which includes, apart from thioredoxins 
from different species, various low molecular weight compounds such as hydrogen 
peroxide, selenite and DTNB (131). Mammals, including humans, have two major 
isoforms of TR, TR1 which is cytosolic and TR2 which is mitochondrial. 
 
Thioredoxin reductase has been suggested to be a drug target for certain anticancer 
drugs such as cis-platin and arsenic trioxide acting through alkylation of the highly 
reactive selenocysteine. Since this falls outside of the scope of this thesis, the 
interested reader is encouraged to seek further information in the following reviews 
(132, 133).  
 
Interestingly, although null mutations for TR1 are embryonically lethal in mice 
(134, 135), the gene is dispensable later if glutathione is present. This was 
demonstrated by conditional knockouts which allowed for normal growth and 
proliferation of hepatocytes – even under conditions of rapid growth such as in the 
re-growth phase after a partial hepatectomy (136, 137). This raises questions about 
the validity of TR1 as a potential drug target in cancer therapies, although a toxic 
gain of function mechanism or combination with other drugs targeting glutathione 
dependent pathways could be viable. 
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1.6.4 Glutaredoxin 
Given the role of thioredoxin as an electron donor for ribonucelotide reductase, it 
was surprising that mutants of phage T7-negative E. coli (115), without detectable 
thioredoxin activity (117, 138), were viable, exhibited an almost normal phenotype 
and had the ability to synthesize DNA. In 1976, this led to the discovery of another 
protein which was able to act as an electron donor for RNR. Since the activity was 
dependent on glutathione, it was named glutaredoxin (138) which was subsequently 
purified to homogeneity (139) and further characterized (140).  
 
Glutaredoxins share the same basic architecture with thioredoxins (the thioredoxin 
fold), although they are typically smaller with four β-strands, three α-helices and a 
molecular weight of approximately 10 kDa. Another class of glutaredoxins, as 
exemplified by E. coli Grx2, is characterized by a molecular weight of 
approximately 24 kDa and an overall fold similar to that of glutathione-S-
transferases (141). The most commonly found active site amongst glutaredoxins is 
the dithiol motif CPYC (142).  However, monothiol glutaredoxins do exist as 
exemplified by E. coli Grx4 which encodes a CGFS active site (143, 144). 
 
In organisms, like E. coli and humans, which have both the thioredoxin and 
glutaredoxin system present, some functions overlap whereas other functions are 
distinct for the glutaredoxin system. The former is exemplified by the reduction of 
ribonucleotide reductase and PAPS reductase, whereas the latter is exemplified by 
glutaredoxins role in  reduction of glutathionylated proteins (142). 
 
 
1.6.5 Glutathione and glutathione reductase 
Glutahione (L-ɣ-glutamyl-L-cysteinylglycine, GSH) is a tri-peptide composed of 
glutamic acid, cysteine and glycine. GSH is synthesized by the enzymes ɣ-
glutamylcysteinyl synthethase (GshA) and glutathione synthethase (GshB) in a two 
step process requiring ATP. Apart from its role in the reduction of glutaredoxins, 
GSH has a wide variety of functions including direct neutralization of reactive 
oxygen species (ROS) and detoxification of xenobiotics (145). Glutathione 
reductase (GR) is the FAD containing enzyme responsible for regeneration of 
glutathione (GSH) from the oxidized form (GSSG) at the expense of NADPH 
(146). 
 
 
1.6.6 The thioredoxin and glutaredoxin systems in E. coli 
Combined null mutants of Grx1 and Trx1 were not viable unless the growth 
medium was supplemented with cysteine. However, they had a capacity for RNR 
reduction which led to the conclusion that either Trx1 or Grx1 is required for 
reduction of PAPS reductase, but that an alternative electron donor for RNR exists 
(147). 
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An E. coli strain with null mutations for Trx1 and Grx1 (148), was used to isolate 
two additional glutaredoxins (Grx2 and Grx3). Grx2 was unable to reduce E. coli 
RNR, whereas Grx3 showed an approximate catalytic efficiency of 2% relative to 
Grx1 (149). Given the low capacity of Grx3 for RNR reduction, the physiological 
role was not immediately clear.   
 
Eventually, it was established that E. coli had at least one more redoxin capable of 
TR dependent reduction of disulfides (150). Trx2 was identified and shown to be 
capable of reducing insulin and the type Ia RNR but not the type Ib (151). 
 
A fourth glutaredoxin (Grx4), with a monothiol CGFS active site was discovered in 
E. coli. Although likely essential, the exact physiological role is currently a bit 
unclear (143), given that it cannot replace Trx1, Trx2 or Grx1 in their respective 
roles in reduction of RNR and PAPS reductase. 
 
All in all, E. coli has two thioredoxins and four glutaredoxins and requires either a 
functional thioredoxin or glutaredoxin system to sustain aerobic growth and 
produce dNTPs in vivo. The thioredoxin can be either Trx1 or Trx2, whereas Grx1 
becomes essential in the absence of a functional thioredoxin sytems (84, 150). 
 
 
1.6.7 Some bacteria do not produce GSH 
Many bacteria do not use GSH – some of which are medically important pathogens 
such as the Staphylococci (S. aureus and the coagulase negative staphylococci 
including S. epidermidis) and Mycobacteria (including M. tuberculosis). This also 
holds true for the B. cereus group (including B. anthracis) and the common model 
organism B. subtilis (152–154).  
 
H. pylori lacks the genes required for synthesis and regeneration of glutathione 
(GR) (86), but instead degrades GSH from the host using the extracellular enzyme 
ɣ-glutamyl transpeptidase (GGT) giving the bacterium access to glutamate (155). 
GGT results in the induction of oxidative stress and is required for colonization of 
the gastric mucosa in animal models (156). H. pylori isolates from patients with 
active peptic ulcer disease have a significantly higher GGT-activity compared to 
isolates from patients without ulcers (157).  
 
The absence of glutathione should make these bacteria heavily dependent on the 
thioredoxin system for reduction of ribonucleotide reductase and protection against 
oxidative stress. 
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1.7 THIOREDOXIN SYSTEMS IN BACTERIA DEVOID OF GSH 
 
1.7.1.1 Helicobacter pylori 
In the sequenced genome of H. pylori 26695, there are two genes annotated as 
thioredoxins and two genes annotated as thioredoxin reductases (86). Windle et al, 
isolated one thioredoxin (Trx1) and one thioredoxin reductase from its native 
source, verified their activity and observed that Trx1 is accumulated under 
conditions of stress induced by incubation with anti-H.pylori antibodies (158). 
Another study characterized Trx1 and Trx2 as substrates for TR and electron donors 
for alkyl hydroperoxide reductase (AhpC). Interestingly, the catalytic efficiency of 
Trx1 as a substrate for TR was approximately three-fold lower, predominantly due 
to a six-fold higher Km, relative to the E. coli counterpart. Trx2, with its atypical 
CPDC active-site, showed similar catalytic properties with model disulfides, but 
was unable to reduce AphC (105).  
 
Surprisingly, a combined null-mutant for both Trx1 and Trx2 in H. pylori was 
viable. However, it could only be isolated in an atmosphere with very low oxygen 
tension (2%), grew slowly to a low final density and was very sensitive to various 
forms of oxidative and nitrosative stress (159). This might indicate the existence of 
an alternative pathway for reduction of RNR and other protein disulfides. 
 
The annotation of a second gene as a thioredoxin reductase, based on its sequence 
similarity to TR from other species (86) opened up the possibility of further 
redundancy in the system. However, the gene (HP1164) does not encode a protein 
with a potential CXXC active site. The protein was later shown, rather than acting 
as a TR, to be a combined flavodoxin and quinone reductase and should be 
reannotated accordingly (160). Thus, H. pylori appears to have only one TR. 
 
Although essentiality for the thioredoxin system has not been shown in vitro, this is 
likely the case in vivo, given the very fragile phenotype for the combined Trx1 and 
Trx2 null-mutant. 
 
 
1.7.1.2 Bacillus anthracis, cereus and subtilis  
In B. subtilis, Trx and TR are both essential for growth on rich laboratory media 
(89, 161). This essentiality could be overcome by the supplementation of the 
growth medium with deoxyribonucleotides and one of the two sulfur containing 
amino acids, cysteine or methionine. However, the growth was still severely 
retarded, the sporulation efficiency was decreased by more than five orders of 
magnitude and the Cytochrome c oxidase activity decreased by more than 99%  
(162).  
 
Under certain conditions, conditional null mutants of Trx in B. subtilis which are 
not dependent on added inducer can be obtained. However, this can be attributed to 
the general leakiness of the promoter and the accumulation of suppressor mutations, 
allowing for read-through into the gene (162–164).  
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In B. cereus, very little has been published with regards to the thioredoxin systems. 
There is one article describing that B. cereus NrdH can function as an electron 
donor for the type Ib RNR of both B. cereus and B. anthracis (79). As for the 
situation in B. anthracis, to the best of our knowledge, nothing had been published 
previously. This was addressed in paper II (106) as will be discussed in more detail 
later. 
 
 
1.7.1.3 Staphylococcus aureus 
Aharonowitz and colleagues studied the thioredoxin system from S. aureus and 
observed that both Trx and TR were upregulated on a transcriptional level when 
exposed to oxidative stress. Furthermore, they were unable to isolate null mutants of 
the gene encoding TR, suggesting that it is essential (165). This was later 
corroborated by another study which utilized transposome based techniques to find 
essential genes. This study suggested that both Trx and TR are essential (97). 
Although none of these studies fulfill the formal criteria for designating a gene as 
essential (as discussed in section 1.2), they are strongly suggestive of essentiality. 
 
In a later study, an NrdH-redoxin was identified which was not part of the usual 
NrdHIEF operon. The active site of the protein was CPPC instead of the CVQC 
sequence found in E. coli NrdH. The protein was active as a general disulfide 
reductase and could transfer electrons to the type Ib RNR, albeit with a low activity. 
The gene encoding NrdH was found to be non-essential and disruption of it was not 
associated with any obvious phenotype (98). 
 
 
1.7.1.4 Bacteroides fragilis 
B. fragilis is an aerotolerant, Gram-negative anaerobe. It is the most commonly 
isolated anaerobe in clinical samples and causes septicemia and abscesses. 
Important for its pathogenic potential is likely its relatively high tolerance for 
oxygen compared to other anaerobes. 
 
Recently, TR was shown to be a key component for oxygen tolerance and for 
protection against oxidative stress in B. fragilis. Furthermore, a strain in which the 
gene encoding TR had been deleted, was severely attenuated and unable to form 
intraperitoneal abscesses in a mouse model (166). On a genomic level, the 
bacterium seems to have six different thioredoxins, out of which one is essential. 
Some of the other, nonessential thioredoxins, appear to be important for protection 
against oxidative stress (167). So far, no data on the pure proteins has been 
published. This could help verifying which of the six are actual thioredoxins and 
which might have other functions in the cell. 
 
  
   21 
 
1.8 BACILLITHIOL – AN ALTERNATIVE TO GSH? 
Some bacteria, including B. anthracis, B. subtilis and S. aureus produce the recently 
described low molecular weight thiol, bacillithiol (BSH) which is present at 
approximately 30-fold lower concentrations than GSH in E. coli (154).  
 
The role of BSH is however, still a bit unclear given that strains with gene knock-
outs abolishing synthesis of BSH in both B. subtilis (168) and B. anthracis (169) are 
viable, without obvious growth defects. Strains unable to produce BSH do however 
exhibit decreased sporulation efficiency, increased sensitivity to extremes of pH and 
ionic strength as well as increased sensitivity to the antibiotic fosfomycin (168, 
169).  
 
This does not paint the picture of attractive drug-targets for antibiotic development. 
Given the essentiality of TR and Trx1 in B. subtilis (89, 161), and the highly likely 
essentiality of TR and Trx in S. aureus (97, 165) a role for BSH as a substitute for 
GSH seems somewhat unlikely. 
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2 AIMS OF THE THESIS 
The overall goals of this thesis were to characterize bacterial thioredoxin systems as 
potential drug targets and to develop inhibitors thereof. Since the thioredoxin 
system is generally dispensable in bacteria which produce glutathione, the focus 
was on bacterial species devoid of glutathione. A special emphasis was given to H. 
pylori, the causative agent behind gastroduodenal ulcers, gastric cancer and type B 
gastritis, as a representative for slow growing, chronic pathogens and B. anthracis, 
the causative agent of anthrax, for rapidly growing bacteria causing fulminant 
disease. Part of the thesis project was also devoted to methodological development 
in the area of cloning and recombinant protein expression. Some of the specific 
aims are listed below with the roman numerals denoting in which paper they have 
been addressed: 
 
 To gain new structural insight on bacterial thioredoxin reductases in general, 
and the one from H. pylori in particular (I). 
 
 To characterize the thioredoxin systems from B. anthracis as general protein 
disulfide reductases and electron donors for the essential protein 
ribonucleotide reductase. Furthermore, to sort out the apparent, several fold, 
redundancy suggested by the annotations of the genome (II). 
 
 To characterize ebselen as an inhibitor of bacterial thioredoxin reductases on 
a biochemical and bacteriological level (III, IV). 
 
 To establish a structure-activity-relationship for ebselen and derivatives 
thereof as inhibitors of bacterial thioredoxin reductases and as antibacterial 
compounds (IV).  
 
 To develop a cloning methodology, retaining the flexibility of the 
Restriction Free (RF) cloning method while improving speed, simplicity and 
cost-effectiveness (II).  
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3 METHODOLOGY 
Most projects require a number of different techniques, some of which are 
laborative in their nature and some of which are computer based. A few of the 
methods where some kind of development was undertaken are discussed below. 
 
3.1 GENE CLONING 
In this thesis gene cloning, or simply cloning, specifically relates to the process in 
which a copy of a gene is transferred from the genome of an organism into another 
vector such as a plasmid. A plasmid is a short, circular piece of DNA which is 
replicated independently from the chromosomal DNA and is commonly present in 
many bacteria. A plasmid used for this purpose typically encodes an origin of 
replication (ORI) where replication starts, integration sites for the desired gene and 
an antibiotic resistance marker which allows the host to survive under selective 
pressure of the specific antibiotic. Plasmids intended for recombinant protein 
expression also encodes a promoter region which allows the RNA polymerase to 
bind and initiate transcription, where the T7-polymerase system is popular (170, 
171). 
 
A typical traditional approach to cloning involves the PCR-amplification of the 
gene of interest, gel-purification of the amplified fragment, digestion with 
restriction endonucelases of the fragment and vector, annealing, ligation and 
transformation into recipient bacteria. This approach suffers from limited flexibility, 
given that specific restriction sites needs to be considered, and is inherently labour 
intensive.  
 
In the era of structural genomics, the problems of parallelization associated with the 
traditional restriction-ligation cloning resulted in the development of Ligation 
Independent Cloning (LIC-cloning) which lends itself to parallel cloning of multiple 
targets. This method does however require special adaptation of the vectors (172) 
limiting the flexibility.  
 
Another method, which addresses the limitations with regards to flexibility, is 
Restriction Free (RF) cloning which was originally developed by Geiser and co-
workers (173) and further developed by van den Ent and co-workers who gave the 
method its name (174). The method is composed of an initial PCR, where the gene 
of interest is amplified by forward and reverse primers which are flanked by 
roughly 25 base pairs complementary to the destination vector. After gel 
purification, the PCR-product is used as primers in a linear amplification step, 
where the fragment is inserted in the destination plasmid, after which the mixture is 
treated with DpnI to digest the parental plasmid. The product is then used to 
transform E. coli. Although flexible, the method is still rather labour intensive, time 
consuming and does poorly lend itself to parallelization. 
 
These limitations prompted us to develop ERF-cloning (Exonuclease dependent 
Restriction Free cloning), which is discussed in more detail in paper II (106). 
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3.2 RECOMBINANT PROTEIN EXPRESSION AND PURIFICATION 
A prerequisite for many comprehensive biochemical investigations is pure protein 
in adequate amounts (usually mg-quantities). Traditionally this has been achieved 
by isolation of the protein from its native source. This is typically both time-
consuming and labour intensive giving a low final yield, unless the protein of 
interest is highly abundant and/or has special properties allowing for simplified 
purification procedures. 
 
With the development in molecular biology (especially in the area of gene cloning 
and with the ever-growing availability of sequenced genomes), recombinant protein 
expression in E. coli has largely taken over as the primary source for proteins for 
biochemical studies. Most often, E. coli harboring the gene of interest on a plasmid 
is grown to mid-log phase at 37
o
C, in a medium containing nutrients in the form of 
yeast extract and digested protein extracts, after which an inducer is added to the 
culture. This inducer, which is typically IPTG (Isopropyl β-D-1-
thiogalactopyranoside) as for the T7-system, induces expression of the gene of 
interest (171). Expression of target proteins with IPTG often results in high 
expression of target protein, but can result in the formation of insoluble protein 
aggregates. Furthermore, the massive induction of expression often limits the final 
density of the bacterial culture to an OD600 of approximately 2-3, thus lowering the 
final yield. These problems are especially prominent when protein production is 
done at 37
o
C, but can sometimes be partially circumvented by lowering the 
cultivation temperature, resulting in slower growth rates. Some structural genomics 
projects utilize a combination of rich, buffered mediums with expression of proteins 
at low temperature and the use of specialized equipment ensuring maximal aeration. 
This results in increased final cell densities (up to about OD600 = 20) and protein 
levels (172, 175).  
 
Previous investigators have observed that high level production of the desired 
protein is sometimes induced without any exogenously added inducer (176, 177). 
However, the mechanism behind this was not fully understood.  
 
In a seminal paper from 2005, FW Studier dissected the mechanism and found that 
the unintended induction was due to residual lactose from the casein hydrolysate 
which is converted to allolactose, in turn driving expression of the gene. This led to 
the development of auto-induction, in which a low level of glucose prevents uptake 
of lactose and permits growth to high densities. When glucose is exhausted, lactose 
which is also included in the medium is taken up and the protein of interest is 
produced. This allowed for high-density cultivation (final OD600 up to ≥ 20) without 
the need constant observation of growth or specialized equipment such as 
fermentors (178). The method was further developed by BG Fox and co-workers 
(179, 180). 
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When a protein is recombinantly expressed in E. coli, intracellular expression is 
usually opted for, which means that the protein has to be extracted before 
purification. This can be achieved through a number of methods including physical 
methods such as sonication (181), detergents which dissolve the membrane (182), 
enzymes degrading the cell wall (183), compounds interfering with the integrity of 
the LPS layer (such as EDTA) and freeze-thaw treatments which disrupts the inner 
membrane through the formation of ice crystals (184). Often, methods need to be 
combined for efficient lysis. 
 
In paper II (106), we used auto-induction for expression of the target proteins. By 
combining an optimized auto-induction medium with low temperature cultivation, 
we could obtain up to 800 mg of pure protein / litre bacterial culture. Furthermore, 
by including arabinose in the medium, and through the use of the bacterial strain 
XJB(DE3)Autolysis (ZymoResearch), which carries a chromosomal copy of λ-
phage lysozyme under control of the pBAD promoter, we could easily lyse the cells 
by simply resuspending the bacteria in a hypotonic buffer followed by a freeze-thaw 
treatment. This allowed for facile processing of multiple constructs in parallel. 
When combined with nucleases to degrade DNA and RNA, it resulted in low-
viscosity lysates, suitable for downstream processing. 
 
A problem often encountered when FAD-containing proteins are over-expressed to 
very high levels, is that the cellular machinery for synthesis of FAD cannot keep up. 
It has previously been counteracted by including FAD in the lysis buffer, increasing 
the amount of holo enzyme (176). This strategy was adopted in both paper I (185) 
and II (106). In paper II, it resulted in a seven-fold increase in holo enzyme, 
compared to the unsupplemented control, as determined by the ratio of FAD 
absorbance to protein concentration (determined by the method of Lowry). 
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I  
Helicobacter pylori  is heavily dependent upon the thioredoxin system for growth 
and defence against oxidative stress (159). The catalytic properties for the TR-Trx1 
couple is also quite different compared to the E. coli equvivalent. When H. pylori 
Trx1 was used as a substrate for its TR, Km was found to be six-fold higher (105) 
than for the E. coli couple. At the time, crystal structures of thioredoxin reductases 
from two different bacteria were available; several structures of the E. coli enzyme 
(124–127) , and one of the enzyme from M. tuberculosis (186). Based on this, we 
wanted to investigate the thioredoxin reductase from this gastric pathogen from a 
structural point of view, with the hope of obtaining information that could be of 
value in drug development.  
 
Crystals were rapidly obtained in the initial screens for the enzyme without added 
NADP
+
. However, despite extensive optimization, crystals of this form diffracted to 
3-4Å at best and were not pursued further. 
 
When instead enzyme mixed with NADP
+
 was used, crystals growing as thin plates 
appeared in the initial screens. Unfortunately, these crystals were very hard to 
obtain reproducibly and diffracted to a maximum of 2.8Å.Through the use of a 
combination of additives, detergents and streak-seeding, we were able to obtain 
reproducibly growing crystals which still grew as plates. After a couple of rounds of 
streak-seeding, crystals growing as thick, bright yellow rods (Figure 3) were 
obtained. These crystals reproducibly diffracted to better than 2Å resolution. 
 
 
Figure 3. Helicobacter pylori thioredoxin reductase crystallized in the presence of 
NADP
+
.  
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We were able to determine the crystal structures of the oxidized and reduced forms 
of the enzyme at 1.7 and 1.45 Å resolutions, respectively. At the time, this 
represented the most highly resolved crystal structures of a bacterial thioredoxin 
reductase. 
 
The overall architecture of the enzyme (Figure 4) was quite similar to the one from 
E. coli (124–127) and M. tuberculosis (186). However, there are distinct 
differences, especially in the thioredoxin binding area, which is less negatively 
charged in the H. pylori enzyme compared to the E. coli counterpart. This may 
potentially explain species-specific recognition of Trx by TR. 
 
 
Figure 4. Helicobacter pylori thioredoxin reductase. Ribbon representation of the dimer 
of reduced H. pylori thioredoxin reductase (PDB code: 2Q0L). Bound FAD and NADP
+
 are 
shown in stick representation. Subunits are coloured by domain organization, with the 
FAD-binding domains in blue and the NADPH-binding domains in yellow (Picture 
courtesy of Dr. Edvard Wigren). 
  
 
The structural information could potentially be used for rational design and 
optimization of inhibitors, but has hitherto predominantly been used as a reference 
for modeling and structure determinations (187–193). 
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4.2 PAPER II 
To broaden the scope of the thesis, we decided to take a closer look at the 
thioredoxin systems from B. anthracis, the causative agent of anthrax. Although 
neither H. pylori nor B. anthracis produce glutathione, they are quite different in a 
number of other aspects as discussed in some detail the introduction. When this 
project was started, there was no information available on the thioredoxin systems 
from B. anthracis or the closely related B. cereus. At the time of publication, there 
was one article demonstrating that B. cereus NrdH together with TR could reduce 
RNR from B. anthracis (79). Since the focus of this article was primarily on the 
metal content and radical in RNR, other possible combinations were not taken into 
account. 
 
Our goal was to try to identify all possible thioredoxin reductases, thioredoxins and 
NrdH-redoxins in B. anthracis and to characterize the flow of electrons from 
NADPH to the terminal substrates with an emphasis on ribonucleotide reductase. 
 
Initial searches showed that a large number of genes were annotated as potential 
thioredoxin reductases, thioredoxins and NrdH-redoxins, some of which lacked a 
potential active site (CXXC). Based on this, we decided on a more structured 
bioinformatic strategy, where the primary search was followed by the step-wise 
exclusion of genes without a potential active site, and those with a predicted 
extracellular localization (Figure 5). 
 
 
 
 
 
Figure 5. Overview of the bioinformatic strategy. Annotated genes from the genome of 
B. anthracis Ames (194) were accessed through the RefSeq database (195). Retrieved genes 
were manually inspected for a potential active site (CXXC) and genes were excluded when 
such a sequences was absent. Subcellular localizations were predicted using PSORTb and 
genes with a predicted extracellular localization were excluded. The rest of the genes were 
included in the experimental set and were cloned, expressed, purified and characterized. 
 
  
Results primary search
4 potential thioredoxin reductases
6 potential thioredoxins
3 potential NrdH-redoxins/grx-like
2 potential TR
5 potential Trx
3 potential NrdH/grx-like
Experimental set
2 potential TR
3 potential Trx
3 potential NrdH/grx-like
3 sequences excluded
(lack of  potential active-
site (CXXC))
2 sequences excluded
(predicted extracellular
localization)
Cloning, expression, 
purification and 
characterization
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For cloning of the genes, we developed a new cloning methodology which we 
named ERF-cloning. This cloning method retains the flexibility of restriction free 
cloning (173, 174) while significantly improving speed, ease of parallelization and 
cost effectiveness. This method could be useful in low-medium throughput 
laboratories where flexibility combined with speed should be of greatest interest. In 
high throughput laboratories, the ease of parallelization might be more important. 
 
When we started characterizing the proteins, it quickly became apparent that there 
were few active players. Out of the two possible thioredoxin reductases, only TR1 
was active. Potential TR2 was inactive in combination with all six potential 
redoxins in both the assays and was not reducible by NADPH or NADH. Out of the 
three potential thioredoxins, two were active. Trx1 could reduce both the low 
molecular weight disulfide DTNB and insulin which serves as a model for general 
protein disulfides. Trx2 on the other hand, could only reduce DTNB. This contrasts 
to the situation in H. pylori, where Trx2 can reduce both DTNB and insulin (105), 
despite an identical CPDC active site. Out of the three potential NrdH-redoxins, 
only one was active. When the different redoxins were characterized in more detail 
as substrates for TR, Trx1 was found to be superior, giving three-fold and 20-fold 
higher catalytic efficiencies than Trx2 and NrdH, respectively. Interestingly, the 
catalytic efficiency for the TR1-Trx1 couple is almost five-fold lower than the 
equivalent from E. coli (196).  
 
When all of the potential redoxins were screened as electron donors for B. anthracis  
RNR, only Trx1 and NrdH were active with the manganese form of the enzyme, 
whereas none of them stimulated the activity of the iron form of RNR. This 
strengthens the notion that type Ib RNRs are indeed manganese containing enzymes 
(72–74, 76, 79). When Trx1 and NrdH were compared as electron donors for RNR, 
Trx1 was more efficient, giving a seven-fold higher catalytic efficiency, primarily 
due to a six-fold lower Km. This is in contrast to the situation in E. coli, where 
NrdH, but not Trx1 was active as electron donors for its type Ib RNR (119). 
 
To be able to draw relevant conclusions about the physiological roles of the 
different active redoxins, we needed information about relative levels. First we 
studied the relative enzymatic activities in lysates of the non-pathogenic strain B. 
antracis Sterne 7700 (pOX1
-
, pOX2
-
), by incubating the lysates with polyclonal 
antibodies raised against the respective pure proteins. We established that close to 
100% of the enzymatic activity could be attributed to Trx1. To confirm this, we 
developed quantitative western-blots which showed that Trx1 was present at 15 and 
60 times higher concentrations than Trx2 and NrdH, respectively. 
 
Although essentiality of TR1 and Trx1 has not been formally proven in B. 
anthracis, this seems highly likely given results presented in our investigation and 
the essentiality of corresponding genes in related species (89, 161, 165). Based on 
this we suggested that TR1 and Trx1 could constitute attractive drug targets. 
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4.3 PAPER III 
Ebselen(2-phenyl-1,2-benzoisoselenazol-3(2H)-one, Figure 6) was developed as a 
glutathione peroxidase mimic (197) and has been evaluated in phase III clinical 
trials against acute ischemic stroke by the Daiichi Pharmaceutical Company, Japan. 
It showed a favorable safety profile although the treatment effect was not 
statistically significant (198). In 1996, when mammalian TR was discovered to be a 
selenoenzyme, a collaboration was initiated involving Daiichi and the Holmgren 
laboratory. Ebselen was shown to be a substrate for mammalian thioredoxin 
reductase, allowing for TR-dependent detoxification of hydroperoxides. It also 
acted as a superfast oxidant of thioredoxin (199, 200). Furthermore, results from 
this laboratory in 1996, showed that ebselen acted as in inhibitor rather than a 
substrate for E. coli TR. This gave rise to the hypothesis that ebselen could act as an 
antibacterial agent through inhibition of bacterial TRs. 
 
 
 
 
 
Figure 6. Structure of ebselen (2-phenyl-1,2-benzoisoselenazol-3(2H)-one) 
 
 
 
In material provided by Daiichi, ebselen had been found to have antibacterial 
properties against selected bacteria with MIC values down to 0.2µg/ml for S. aureus 
and a rapidly bacteriocidal mode of action through an unknown mechanism (201).  
 
We observed that most of the bacteria sensitive to ebselen lack glutathione. In 
combination with the finding that ebselen inhibits E. coli TR, a mechanism where 
ebselen exerts its action through inhibition of bacterial thioredoxin reductases in 
bacteria devoid of glutathione became likely. 
 
When we tested ebselen as an inhibitor of E. coli TR, we found that it acted as a 
competitive inhibitor with a Ki of 0.5 µM targeting the C-terminal active site 
cysteine (C138). The sulfur analog of ebselen, ebsulfur, where the selenium atom 
has been substituted for a sulfur atom was instead a substrate for the E. coli enzyme 
whereas it acted as an inhibitor of the thioredoxin reductase from H. pylori. This 
difference was interesting, not least given the small, but distinct differences found 
between the two enzymes in paper I (185). 
 
N
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In an attempt to dissect the mechanism, we utilized different E. coli strains with 
various null-mutations in the thioredoxin and glutaredoxin systems. We could see 
that strains with deletions in the systems for synthesis or regeneration of glutathione 
were more sensitive to exposure to ebselen than the strains in which parts of the 
thioredoxin system had been deleted.  
 
To further corroborate our hypothesis, we exposed different logarithmically 
growing E. coli strains to ebselen and could show that growth-arrest correlated with 
in vivo oxidation of thioredoxin 1 in strains unable to produce glutathione. 
 
In the last part of the paper, we expanded the set of sensitive bacteria with H. pylori 
and M. tuberculosis, both of which are unable to synthesize glutathione.   
 
The combined data demonstrate that ebselen is a competitive inhibitor of E. coli TR 
in vitro acting by binding to the active site cysteines. Furthermore, that inhibition of 
TR and direct oxidation of Trx might be important mechanisms of action for 
ebselen in vivo, in bacteria devoid of glutathione.  
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4.4 PAPER IV 
 
In this paper, we took the next logical step and characterized ebselen and 
derivatives thereof as inhibitors of B. anthracis thioredoxin reductase. 
 
When we compared the sequences of TR from B. antracis with some other 
members of the low-GC group of Gram-positive bacteria, we could see that the 
degree of conservation was high with 86% identity for B. subtilis and 73% identity 
for S. aureus. The identity was lower for the Gram-negative bacterium E. coli which 
exhibited 38% identity.  
 
Ebselen was verified as an inhibitor of B. anthracis TR with a IC50 value of 1.0 µM 
assayed with 25nM TR and 2.5µM Trx1 and DTNB as the terminal substrate. When 
a series of 12 analogs were evaluated, IC50 values varied from 70nM to 14.8µM. 
An IC50 value of 70 nM, as observed for the most potent compound (compound nr 
12, please refer to manuscript IV for structures), represents a close to stoichiometric 
concentration with respect to available active sites in TR. The second most potent 
inhibitor of the enzyme was compound nr 9 which gave an IC50 value of 370nM. 
This represents close to a three-fold increase in potency relative to parental ebselen. 
 
In the next part of the study, we tested the compounds against B. subtilis as a 
substitute for B. anthracis, which requires special considerations for use. The 
compounds were evaluated based on two fundamental parameters – MIC and MBC. 
The MIC (Minimal Inhibitory Concentration) is defined as the lowest concentration 
of drug preventing all visible growth of bacteria. MBC (Minimal Bacteriocidal 
Concentration) is defined as the lowest concentration of drug resulting in a 
minimum of 99.9% reduction in CFU (Colony Forming Units) during 24 hours, 
where a CFU is assumed to represent one viable bacterium in the culture. The MIC 
value was compared to the previously established IC50 value for a human cell line 
(HEK 293) (202) and selectivity indices (SI) were calculated by dividing the IC50 
for HEK cells with the MIC for B. subtilis.  
 
The MIC values were found to vary between 0.4µM (0.12µg/ml) and >16µM. The 
most potent group of compounds, with a MIC of 0.4-0.5µM included parental 
ebselen, compound nr 9 and compound nr 12, but also a 2-methyl, 4-cloro 
substituted derivative (compound nr 3). MBC values were found at 1-2 times the 
MIC values, suggesting a general bacteriocidal mode of action. Selectivity indices 
were found to vary between <3.4 and >400. The group of compounds with the 
highest selectivity indices (>400 – 160) included compounds 1, 3 and 9. Notably, 
compound nr 12 gave a modest SI of 25. 
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On a general note, inhibitory activity on the pure enzyme showed a reasonably good 
correlation to the effects seen on B. subtilis, although exceptions exist. For example, 
compounds with carboxylic acid substituents gave reasonable IC50 values, which 
were 4.5 – 5 times higher than parental ebselen, but MIC values which were >32 
times higher. Since these carboxylic acid substituents are likely de-protonated and 
negatively charged under physiological pH, we speculate that this might impair 
permeability. Furthermore, compound 12, which was 15-fold more potent as an 
inhibitor of the pure enzyme gave the same MIC value as parental ebselen. This 
might be attributable to decreased permeability due to the larger size of the 
molecule. 
 
The most powerful technique to obtain structural information about a protein is X-
ray crystallography. Structural information can potentially be used for rational 
design and /or optimization of inhibitors (31). Therefore, a long-standing goal has 
been to crystallize a complex between a bacterial TR and ebselen. However, co-
crystallization of preformed complexes between TRs from different species and 
ebselen has hitherto been unsuccessful. The same goes for post-crystallization 
soaking of crystals (data not shown).  
 
Therefore, we decided to characterize the complex between the C135S mutant of B. 
anthracis TR and ebsulfur where ebsulfur is an analog of ebselen in which the 
selenium atom has been substituted for with sulfur. The most important reason for 
choosing ebsulfur over ebselen, is the somewhat higher solubility of the former.  
 
Mass-spectrometry verified close to complete complex formation between ebsulfur 
and the protein in a 1:1 stoichiometry. The complex eluted as a nice symmetrical 
peak in size-exclusion chromatography which should be a good starting point for 
crystallization. A good behavior in size-exclusion chromatography appears to have 
a positive predictive value for crystallization success (203).  
 
All in all, the most promising compound was compound nr 9, which gave the 
second lowest IC50 value (370 nM) for the enzyme, the lowest MIC (0.4µg/ml) and 
the best selectivity index (>400). Hopefully this or another analog based on the 
structure-activity-relationship established in this study can be developed into an 
antibiotic for the treatment of anthrax. Given the high degree of similarity between 
TRs in the particular group of bacteria, data can likely be extrapolated to other 
bacteria such as S. aureus – at least on an enzymatic level. 
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5 CONCLUDING REMARKS 
 
Since antimicrobial resistance is a major problem and continued development of 
new antibiotics is needed, a few important questions arise: 
 
 Are bacterial thioredoxin systems good drug targets? 
 
 Does ebselen represent an attractive drug candidate for further 
development? 
 
 Is the choice of H. pylori and B. anthracis as primary study objects 
adequate? 
 
The essentiality criteria is reasonably well fulfilled for representative bacteria (B. 
subtilis, S. aureus and to a lesser extent H. pylori). There seems to be a general 
trend that bacteria devoid of glutathione are heavily dependent on thioredoxin and 
thioredoxin reductase for synthesis of DNA and protection against oxidative stress. 
 
Thioredoxin reductase is present in the host (humans), but is dispensible (at least in 
mice) after birth, due to the presence of the glutaredoxin system. Furthermore, 
thioredoxin reductase is sufficiently different in mammals and bacteria to allow for 
selective targeting. 
 
With regards to the possible spectrum of activity for an inhibitor, it includes distinct 
members from different groups such as Gram-negatives (including as H. pylori), 
Gram-positives (including S. aureus and B. anthracis) and acid fast bacilli 
(including M. tuberculosis). Interestingly, a large part of the normal flora (including 
E. coli) does have glutathione which could allow for selective targeting with fewer 
side effects. 
 
 Bacterial thioredoxin systems are good drug targets in bacteria devoid of 
glutathione (II-IV).  
 
 Species/ group specific differences with respect to structure and function of 
TRs and Trxs need to be taken into account when evaluating inhibitors (I, 
III, IV).  
 
When ebselen is considered as a potential antibiotic lead compound, several things 
speak in its advantage. The favourable toxicity profile of ebselen as a phase III drug 
against ischemic stroke is encouraging and its ability to work as an antioxidant in 
mammalian systems represent a possible added bonus. The favourable selectivity 
indices are also encouraging as well the novel mechanism of action.  
 
 Ebselen and analogs thereof represent attractive leads for antibiotic 
development (III, IV).  
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The need for development of novel antibacterial targeting H. pylori is warranted on 
the direct basis of its common occurrence as a causative agent behind peptic ulcer 
disease and the increasing resistance seen amongst clinical isolates. 
 
As for B. anthracis, the question is a bit harder given that there are only about 5000 
cases annually, worldwide. Thus, it can hardly be considered a major public health 
problem as of today. However, antibiotic development should ideally be one step 
ahead. Furthermore, the ease with which resistant strains can be generated in the 
laboratory is problematic. Additionally, for systems which are highly conserved 
between B. anthracis and other bacteria, extrapolation to other species might be 
possible. 
 
H. pylori and B. anthracis represent the opposite sides of the spectrum with respect 
to many basic physiology features (such as Gram-stain, sporulation ability and 
oxygen tolerance/requirements) and the type of disease they cause (slow, chronic 
infections vs rapidly progressing). 
 
 Continued development of antibiotics targeting H. pylori and B. anthracis is 
warranted. 
 
 H. pylori and B. anthracis are interesting species from a redox perspective 
and especially the thioredoxin systems deserve investigation given the 
absence of glutathione (I – IV).  
 
 Data obtained using the thioredoxin system from B. anthracis can likely be 
extrapolated to other bacteria such as S. aureus ( II and IV). 
 
 
All in all, the data presented herein strongly suggest that bacterial thioredoxin 
systems represent good drug targets in bacteria devoid of glutathione. Furthermore, 
ebselen represents an interesting starting point for development of a novel class of 
antibacterials. This class could potentially be used to treat a wide variety of 
infections including anthrax, peptic ulcers and tuberculosis. 
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